These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 35905032)

  • 1. Early Initiation of Antitumor Necrosis Factor Therapy Reduces Postoperative Recurrence of Crohn's Disease Following Ileocecal Resection.
    Axelrad JE; Li T; Bachour SP; Nakamura TI; Shah R; Sachs MC; Chang S; Hudesman DP; Holubar SD; Lightner AL; Barnes EL; Cohen BL; Rieder F; Esen E; Remzi F; Regueiro M; Click B
    Inflamm Bowel Dis; 2023 Jun; 29(6):888-897. PubMed ID: 35905032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endoscopic Postoperative Recurrence in Crohn's Disease After Curative Ileocecal Resection with Early Prophylaxis by Anti-TNF, Vedolizumab or Ustekinumab: A Real-World Multicentre European Study.
    Yanai H; Kagramanova A; Knyazev O; Sabino J; Haenen S; Mantzaris GJ; Mountaki K; Armuzzi A; Pugliese D; Furfaro F; Fiorino G; Drobne D; Kurent T; Yassin S; Maharshak N; Castiglione F; de Sire R; Nardone OM; Farkas K; Molnar T; Krznaric Z; Brinar M; Chashkova E; Livne Margolin M; Kopylov U; Bezzio C; Bar-Gil Shitrit A; Lukas M; Chaparro M; Truyens M; Nancey S; Lobaton T; Gisbert JP; Saibeni S; Bacsúr P; Bossuyt P; Schulberg J; Hoentjen F; Viganò C; Palermo A; Torres J; Revés J; Karmiris K; Velegraki M; Savarino E; Markopoulos P; Tsironi E; Ellul P; Calviño Suárez C; Weisshof R; Ben-Hur D; Naftali T; Eriksson C; Koutroubakis IE; Foteinogiannopoulou K; Limdi JK; Liu E; Surís G; Calabrese E; Zorzi F; Filip R; Ribaldone DG; Snir Y; Goren I; Banai-Eran H; Broytman Y; Amir Barak H; Avni-Biron I; Ollech JE; Dotan I; Aharoni Golan M
    J Crohns Colitis; 2022 Dec; 16(12):1882-1892. PubMed ID: 35895074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ustekinumab and vedolizumab for the prevention of postoperative recurrence of Crohn's disease: Results from the ENEIDA registry.
    Mañosa M; Fernández-Clotet A; Nos P; Martín-Arranz MD; Manceñido N; Carbajo A; Hinojosa E; Hernández-Camba A; Muñoz-Pérez R; Boscá-Watts M; Calvo M; Sierra-Ausín M; Sánchez-Rodríguez E; Barreiro-de Acosta M; Núñez-Alonso A; Zabana Y; Márquez L; Gisbert JP; Guardiola J; Sáinz E; Delgado-Guillena P; Busquets D; van Domselaar M; Girona E; Lorente R; Casas-Deza D; Huguet JM; Maestro S; Cabello MJ; Castro J; Iborra M; Cañete F; Calafat M; Domènech E;
    Dig Liver Dis; 2023 Jan; 55(1):46-52. PubMed ID: 35948459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-TNF Agents and New Biological Agents (Vedolizumab and Ustekinumab) in the Prevention and Treatment of Postoperative Recurrence After Surgery in Crohn's Disease.
    Gisbert JP; Chaparro M
    Drugs; 2023 Sep; 83(13):1179-1205. PubMed ID: 37505446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Appearance of the Bowel and Mesentery During Surgery Is Not Predictive of Postoperative Recurrence After Ileocecal Resection for Crohn's Disease: A Prospective Monocentric Study.
    Bislenghi G; Van Den Bossch J; Fieuws S; Wolthuis A; Ferrante M; de Hertogh G; Vermeire S; D'Hoore A
    Inflamm Bowel Dis; 2024 Oct; 30(10):1686-1695. PubMed ID: 37793044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prophylactic Versus Endoscopy-driven Treatment of Crohn's Postoperative Recurrence: A Retrospective, Multicentric, European Study [PORCSE Study].
    Geldof J; Truyens M; Hanssens M; Van Gucht E; Holvoet T; Elorza A; Bouillon V; Barros S; Martins V; Argyriou K; Potamianos S; Diculescu M; Stroie T; Bossuyt P; Moens A; Theodoraki E; Koutroubakis IE; Pedro J; Fernandes S; Nikolaou P; Karmiris K; Baert FJ; Ferreiro-Iglesias R; Peeters H; Claeys S; Casanova MJ; Eder P; Porter RJ; Arnott I; Karakan T; Mesonero F; Revés J; Van Dyck E; Jauregui-Amezaga A; Mañosa M; Rivière P; Marquez Mosquera L; Portela F; Pimentel R; Lobaton T
    J Crohns Colitis; 2024 Aug; 18(8):1202-1214. PubMed ID: 38243807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early Ileocecal Resection for Crohn's Disease Is Associated With Improved Long-term Outcomes Compared With Anti-Tumor Necrosis Factor Therapy: A Population-Based Cohort Study.
    Agrawal M; Ebert AC; Poulsen G; Ungaro RC; Faye AS; Jess T; Colombel JF; Allin KH
    Gastroenterology; 2023 Oct; 165(4):976-985.e3. PubMed ID: 37321356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postoperative Safety Profile of Minimally Invasive Ileocolonic Resections for Crohn's Disease in the Era of Biologic Therapy.
    Abd El Aziz MA; Abdalla S; Calini G; Saeed H; Stocchi L; Merchea A; Colibaseanu DT; Shawki S; Larson DW
    J Crohns Colitis; 2022 Aug; 16(7):1079-1088. PubMed ID: 35045164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypoalbuminaemia, Not Biologic Exposure, Is Associated with Postoperative Complications in Crohn's Disease Patients Undergoing Ileocolic Resection.
    Shah RS; Bachour S; Jia X; Holubar SD; Hull TL; Achkar JP; Philpott J; Qazi T; Rieder F; Cohen BL; Regueiro MD; Lightner AL; Click BH
    J Crohns Colitis; 2021 Jul; 15(7):1142-1151. PubMed ID: 33388775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biologics and 30-Day Postoperative Complications After Abdominal Operations for Crohn's Disease: Are There Differences in the Safety Profiles?
    Lightner AL; McKenna NP; Alsughayer A; Harmsen WS; Taparra K; Parker ME; Raffals LE; Loftus EV
    Dis Colon Rectum; 2019 Nov; 62(11):1352-1362. PubMed ID: 31567927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Persistence of Non-tumor Necrosis Factor (TNF) vs. TNF Antagonists for Post-operative Prophylaxis in Crohn's Disease (CD).
    Gu P; Dube S; Lee Y; Yang S; Li D; Haritunians T; Vasiliauskas E; Bonthala N; Syal G; Yarur A; Ziring D; Targan S; Rabizadeh S; Melmed GY; Fleshner P; McGovern DPB
    Dig Dis Sci; 2024 Jan; 69(1):235-245. PubMed ID: 38015321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-World Evidence Comparing Vedolizumab and Ustekinumab in Antitumor Necrosis Factor-Experienced Patients With Crohn's Disease.
    Kappelman MD; Adimadhyam S; Hou L; Wolfe AE; Smith S; Simon AL; Moyneur É; Reynolds JS; Toh S; Dobes A; Parlett LE; Haynes K; Selvan M; Ma Q; Nair V; Burris J; Dorand JE; Dawwas GK; Lewis JD; Long MD
    Am J Gastroenterol; 2023 Apr; 118(4):674-684. PubMed ID: 36508681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rates of Postoperative Recurrence of Crohn's Disease and Effects of Immunosuppressive and Biologic Therapies.
    Rivière P; Vermeire S; Irles-Depe M; Van Assche G; Rutgeerts P; Denost Q; Wolthuis A; D'Hoore A; Laharie D; Ferrante M
    Clin Gastroenterol Hepatol; 2021 Apr; 19(4):713-720.e1. PubMed ID: 32272248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of surgery rates in biologic-naïve patients with Crohn's disease treated with vedolizumab or ustekinumab: findings from SOJOURN.
    Vu M; Ghosh S; Umashankar K; Weber L; Landis C; Candela N; Chastek B
    BMC Gastroenterol; 2023 Mar; 23(1):87. PubMed ID: 36966279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ustekinumab is more effective than azathioprine to prevent endoscopic postoperative recurrence in Crohn's disease.
    Buisson A; Nancey S; Manlay L; Rubin DT; Hebuterne X; Pariente B; Fumery M; Laharie D; Roblin X; Bommelaer G; Pereira B; Peyrin-Biroulet L; Vuitton L;
    United European Gastroenterol J; 2021 Jun; 9(5):552-560. PubMed ID: 33951350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Change in Biologic Class Promotes Endoscopic Remission Following Endoscopic Postoperative Crohn's Disease Recurrence.
    Bachour SP; Shah RS; Joseph A; Syed H; Ali AH; Rieder F; Barnes EL; Axelrad J; Holubar SD; Regueiro M; Cohen BL; Click BH
    J Clin Gastroenterol; 2024 Sep; 58(8):810-817. PubMed ID: 38019054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rate and risk factors of postoperative endoscopic recurrence of moderate- to high-risk Crohn's disease patients - A real-world experience from a Middle Eastern cohort.
    Azzam N; AlRuthia Y; Al Thaher A; Almadi M; Alharbi O; Altuwaijri M; Alshankiti S; Alanazi M; Alanazi A; Aljebreen A; Regueiro M
    Saudi J Gastroenterol; 2022; 28(3):201-208. PubMed ID: 35042320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Indications, Postoperative Management, and Long-term Prognosis of Crohn's Disease After Ileocecal Resection: A Multicenter Study Comparing the East and West.
    Arkenbosch JHC; Mak JWY; Ho JCL; Beelen EMJ; Erler NS; Hoentjen F; Bodelier AGL; Dijkstra G; Romberg-Camps M; de Boer NKH; Stassen LPS; van der Meulen AE; West R; van Ruler O; van der Woude CJ; Ng SC; de Vries AC
    Inflamm Bowel Dis; 2022 Jun; 28(Suppl 2):S16-S24. PubMed ID: 34969091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Ustekinumab and Vedolizumab Among Postoperative Crohn's Disease Patients as Postoperative Prophylaxis and Rescue Therapy: Real-world Data.
    Ertem FU; Rivers CR; Ghaffari AA; Watson AR; Tang G; Schwartz M; Johnston E; Barrie A; Harrison J; Dueker JM; Hartman D; Binion DG
    Inflamm Bowel Dis; 2024 Jul; ():. PubMed ID: 38953641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retreatment with anti-tumor necrosis factor therapy in combination with an immunomodulator for recurrence of Crohn's disease after ileocecal resection results in prolonged continuation as compared to anti-tumor necrosis factor monotherapy.
    Ten Bokkel Huinink S; Beelen EMJ; Ten Bokkel Huinink T; Hoentjen F; G L Bodelier A; Dijkstra G; Romberg-Camps M; de Boer NK; Stassen LPS; van der Meulen AE; West R; van Ruler O; van der Woude CJ; de Vries AC;
    Eur J Gastroenterol Hepatol; 2023 Jan; 35(1):45-51. PubMed ID: 36468568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.